Decoding the Future of Heart Failure — Emerging Strategies in HF with EF ≥40%: Key Takeaways from 2024
Published: 22 November 2024
-
Views:
775
-
Likes:
7
-
Views:
775
-
Likes:
7
Overview
Recorded at American Heart Association 2024 in Chicago, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, Boston, US), Dr Orly Vardeny (University of Minnesota Medical School, Minneapolis, US) and Prof Pardeep Jhund (University of Glasgow, Glasgow, UK) explore cardiometabolic disease in heart failure with mid-range or preserved ejection fraction (HFmrEF and HFpEF).
Leveraging the latest data unveiled at the conference, the expert faculty present essential insights and evidence-based strategies aimed at helping clinicians improve outcomes for patients with HF and associated metabolic conditions. This programme equips clinicians with the most current knowledge to enhance patient care through advanced, targeted interventions tailored to the complex needs of this patient population.
Learning Objectives
- Summarise the long-term burden and current unmet needs for patients with HF and EF ≥40%
- Recall data on new therapies being evaluated in the HFmr/pEF population, including data from the AHA 2024 annual congress
- Describe how non-steroidal MRAs differ in their mechanism of action and elicit their benefits in HF
Target Audience
- Cardiologists
- Internists
- Heart Failure Specialists
- General Practitioners
- Nurse Practitioners
- Cardiovascular Nurses
- Allied Healthcare Professionals
More from this programme
Part 1
Unmet Needs in Individuals With Hf and Ef ≥40%
This session focuses on the disease burden and treatment gaps for patients with HFmrEF/HFpEF. It reviewed the current therapeutic landscape, highlighting key clinical trials evaluating several drug classes.
Part 2
Are Novel MRAs the Answer?
This session explores the potential of novel mineralocorticoid receptor antagonists (MRAs) in treating heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). It examines the rationale for using MRAs in these patients, emphasising the development of non-steroidal MRAs (nsMRAs) over traditional MRAs due to their distinct mechanisms of action. The session also addresses the limited adoption of MRAs in patients with EF >40%, largely due to concerns like hyperkalaemia risk, and introduces the design of the FINEARTS-HF trial, which aims to evaluate the safety and efficacy of these novel agents.
| 1 session | |
| Are Novel MRAs the Answer? | Watch now |
Part 3
New Approaches in HF With EF ≥40%
The key discussion points of this session include recent advances regarding the timing of HF events, the time required to see clinical benefits, ejection fraction considerations, and strategies to manage hyperkalaemia. Additionally, the session highlights ongoing and upcoming trials that aim to address critical gaps in HFmrEF/HFpEF treatment, offering insights into the future landscape of care for these patient populations.
| 1 session | |
| New Approaches in HF With EF ≥40% | Watch now |
Part 4
Modernising Our Practice in the HFmr/pEF Population and Q&A
The panel discusses the evolving treatment landscape and the potential impact on future management strategies, offering practical guidance on implementing new evidence-based therapies in real-world settings.
Faculty Biographies
Muthiah Vaduganathan
Co-Director, Center for Cardiometabolic Implementation Science
Dr Muthiah Vaduganathan is a Cardiologist and Clinical Trialist at Brigham and Women’s Hospital and Harvard Medical School, Boston, US. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He serves as an Associate Editor of JACC and as US national ambassador to the ESC Heart Failure Association. His research focuses on drug development, clinical trials, and implementation of cardio-kidney-metabolic therapies, and he has authored or co-authored more than 700 peer-reviewed publications. He participates on study leadership of ongoing advanced-phase trials in cardio-kidney-metabolism and heart failure.
Orly Vardeny
Associate Professor of Medicine
Dr Orly Vardeny is Associate Professor of Medicine at the University of Minnesota in Minneapolis. Her research interests include maximising the benefit of pharmacologic therapy in patients with heart failure and optimising vaccination strategies in patients with cardiac disorders. She has led several multi-center, randomized clinical trials evaluating influenza vaccines in patients with high-risk cardiovascular disease.
In addition, Dr Vardeny serves as the US national lead investigator and a steering committee member for numerous clinical trials investigating novel therapies in patients with heart failure. Her clinical practice is in the outpatient management of patients with chronic heart failure. She is an Associate Editor for Circulation: Heart Failure and was a writing group member for the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America Guidelines for the Management of Heart Failure.
Pardeep Jhund
Professor in Cardiology, University of Glasgow
Prof Pardeep Jhund is a Professor in Cardiology at the University of Glasgow, UK.
He trained in medicine at the University of Glasgow, and completed his general medical training in Edinburgh. During this time he also graduated with a MSc in Epidemiology from the London School of Hygiene and Tropical Medicine, London, UK.
Prior to this, he graduated from the University of Glasgow with a PhD in cardiovascular epidemiology, under the tutelage of Prof John McMurray, and completed his fellowship at The Brigham and Women’s Hospital, Boston, US.
Prof Jhund has a special interest in heart failure, around which he has published widely in leading international journals.